The Asia Pacific 3D Cell Culture Market should witness market growth of 15.9% CAGR during the forecast period (2022-2028).
The matrix in 3D Spheroids maintains actin filaments and is physiologically significant for cytoskeletal structure, cell polarity, and cell shape in human cells. The three-dimensional design of the cultures enables them to give a model that more closely resembles human tissue in vivo, without the use of animal test subjects.
Due to recent technology advancements involving increasing microplate density, it is now possible to create advanced 3D models for high-throughput testing in high-density formats. Cell-repellent, cost-effective, and compatible with fully automated screening platforms, these are available in 384- and 1536-well formats. Due to the speedy and cost-effective methodologies and technologies that have been established for 3D screening, parallel high-throughput screening procedures have been made possible for testing isogenic pairings of oncogene-related mutations versus the wild-type.
The numerous cell structures within the human body must always be vascularized in order to acquire nutrients and undergo gas exchange. Similarly, 3D cell cultures in vitro necessitate specific amounts of fluid circulation, which can be troublesome for dense 3D cultures in which not all cells receive appropriate nutrient exposure. Because the liver is an extremely vascularized organ, this is especially crucial for hepatocyte cultures.
The Indian pharmaceutical business, which is dominated by a large number of market players, is rising exponentially. India declared in the early 1990s that it has reached an agreement with the World Trade Organization to develop a product patent system beginning in 2005. This declaration marked the beginning of the entry of Indian pharmaceutical firms into the sector of drug discovery and development.
The China market dominated the Asia Pacific 3D Cell Culture Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $226.2 million by 2028. The Japan market is estimated to grow a CAGR of 15.2% during (2022-2028). Additionally, The India market would experience a CAGR of 16.7% during (2022-2028).
Based on Type, the market is segmented into Scaffold-based, Scaffold-free, Microfluidics-based, and Magnetic & Bioprinted. Based on Application, the market is segmented into Cancer & Stem Cell Research, Drug Discovery & Toxicology Testing, and Tissue Engineering & Regenerative Medicine. Based on End-user, the market is segmented into Pharmaceutical & Biotechnology Companies, Research Institutes, Cosmetic Industry, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Thermo Fisher Scientific, Inc., Merck Group, Avantor, Inc., Corning Incorporated, Lonza Group AG, Mimetas B.V., Insphero AG, Emulate, Inc., Tecan Group Ltd., and CN Bio Innovations Ltd.
The matrix in 3D Spheroids maintains actin filaments and is physiologically significant for cytoskeletal structure, cell polarity, and cell shape in human cells. The three-dimensional design of the cultures enables them to give a model that more closely resembles human tissue in vivo, without the use of animal test subjects.
Due to recent technology advancements involving increasing microplate density, it is now possible to create advanced 3D models for high-throughput testing in high-density formats. Cell-repellent, cost-effective, and compatible with fully automated screening platforms, these are available in 384- and 1536-well formats. Due to the speedy and cost-effective methodologies and technologies that have been established for 3D screening, parallel high-throughput screening procedures have been made possible for testing isogenic pairings of oncogene-related mutations versus the wild-type.
The numerous cell structures within the human body must always be vascularized in order to acquire nutrients and undergo gas exchange. Similarly, 3D cell cultures in vitro necessitate specific amounts of fluid circulation, which can be troublesome for dense 3D cultures in which not all cells receive appropriate nutrient exposure. Because the liver is an extremely vascularized organ, this is especially crucial for hepatocyte cultures.
The Indian pharmaceutical business, which is dominated by a large number of market players, is rising exponentially. India declared in the early 1990s that it has reached an agreement with the World Trade Organization to develop a product patent system beginning in 2005. This declaration marked the beginning of the entry of Indian pharmaceutical firms into the sector of drug discovery and development.
The China market dominated the Asia Pacific 3D Cell Culture Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $226.2 million by 2028. The Japan market is estimated to grow a CAGR of 15.2% during (2022-2028). Additionally, The India market would experience a CAGR of 16.7% during (2022-2028).
Based on Type, the market is segmented into Scaffold-based, Scaffold-free, Microfluidics-based, and Magnetic & Bioprinted. Based on Application, the market is segmented into Cancer & Stem Cell Research, Drug Discovery & Toxicology Testing, and Tissue Engineering & Regenerative Medicine. Based on End-user, the market is segmented into Pharmaceutical & Biotechnology Companies, Research Institutes, Cosmetic Industry, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Thermo Fisher Scientific, Inc., Merck Group, Avantor, Inc., Corning Incorporated, Lonza Group AG, Mimetas B.V., Insphero AG, Emulate, Inc., Tecan Group Ltd., and CN Bio Innovations Ltd.
Scope of the Study
By Type
- Scaffold-based
- Scaffold-free
- Microfluidics-based
- Magnetic & Bioprinted
By Application
- Cancer & Stem Cell Research
- Drug Discovery & Toxicology Testing
- Tissue Engineering & Regenerative Medicine
By End-user
- Pharmaceutical & Biotechnology Companies
- Research Institutes
- Cosmetic Industry
- Others
Key Market Players
List of Companies Profiled in the Report:
- Thermo Fisher Scientific, Inc.
- Merck Group
- Avantor, Inc.
- Corning Incorporated
- Lonza Group AG
- Mimetas B.V.
- Insphero AG
- Emulate, Inc.
- Tecan Group Ltd.
- CN Bio Innovations Ltd.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Competition Analysis - Global
Chapter 4. Asia Pacific 3D Cell Culture Market by Type
Chapter 5. Asia Pacific 3D Cell Culture Market by Application
Chapter 6. Asia Pacific 3D Cell Culture Market by End-user
Chapter 7. Asia Pacific 3D Cell Culture Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- Thermo Fisher Scientific, Inc.
- Merck Group
- Avantor, Inc.
- Corning Incorporated
- Lonza Group AG
- Mimetas B.V.
- Insphero AG
- Emulate, Inc.
- Tecan Group Ltd.
- CN Bio Innovations Ltd.
Methodology
LOADING...
